Abbott (ABT)

Executive Summary

Abbott Laboratories is a diversified global healthcare leader with a market capitalization of approximately $179 billion, operating across four core segments: diagnostics, medical devices, nutrition, and established pharmaceuticals. The company's strong portfolio includes the FreeStyle Libre continuous glucose monitoring system, which dominates the diabetes management market, and a growing structural heart business with products like the MitraClip and TriClip for mitral and tricuspid valve repair. Abbott also maintains a leading position in point-of-care diagnostics and pediatric nutrition. Recent financial performance has been driven by robust demand for medical devices and diagnostics, with revenue growth accelerating post-pandemic. The company benefits from durable competitive advantages including proprietary sensor technology, a deep pipeline of next-generation devices, and extensive global distribution networks spanning over 160 countries. Abbott's consistent investment in R&D and strategic acquisitions continues to bolster its long-term growth trajectory, particularly in high-growth areas such as diabetes care, heart failure, and neuromodulation.

Upcoming Catalysts (preview)

• Q4 2026FDA decision on next-generation FreeStyle Libre sensor (Freestyle Libre 4)85% success
• Q3 2026Pivotal trial results for new structural heart device (e.g., TriClip G4 or new TAVR system)70% success
• Q4 2026Launch of new rapid diagnostic test for sepsis or infectious disease60% success